Rise and shine, everyone, another busy day is on the way. Most every day is busy, though, is it not? Well, no matter. Busy is good, as they say. So time to get cracking, which means we would like to invite you to join us for our ritual cup of stimulation, which is a much-needed boost this morning, thanks to a growing to-do list of meetings and phone calls and deadlines — oh my! Meanwhile, we have gathered a few items of interest to help you along. Hopefully, this will be equally stimulating. Hope you conquer the world and stay in touch …

Allergan (AGN) disclosed that its experimental depression drug, rapastinel, failed to improve symptoms more than placebo when added to existing antidepressants in not one but three studies, STAT writes. The drug was the cornerstone of a $560 million deal to buy Naurex four years ago and follows a string of recent setbacks for the big drug maker, which includes new competition to its best-selling Botox treatment. However, Wall Street analysts noted Allergan management recently sent mixed signals about the rapastinel trial results.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy